CCNG2抗体;CCNG2 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12554(CCNG2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12554(CCNG2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The CCNG2 antibody is a crucial tool for studying Cyclin G2 (CCNG2), a member of the cyclin protein family involved in cell cycle regulation. Unlike canonical cyclins that promote cell cycle progression, Cyclin G2 is associated with inhibitory roles, including cell cycle arrest, differentiation, and apoptosis. It interacts with cyclin-dependent kinase (CDK) inhibitors and modulates pathways like the PI3K-AKT and p53 signaling networks. CCNG2 expression is often downregulated in cancers (e.g., breast, ovarian, and liver cancers), suggesting tumor-suppressive functions, though its role can vary depending on cellular context.

CCNG2 antibodies enable the detection and quantification of Cyclin G2 in techniques such as Western blotting, immunohistochemistry, and immunofluorescence. These antibodies are vital for exploring CCNG2's involvement in diseases, including cancer progression, neurodegenerative disorders, and metabolic syndromes. Researchers also use them to study post-translational modifications and subcellular localization of Cyclin G2. which influence its stability and activity. Despite its established role in cell cycle inhibition, some studies report context-dependent pro-proliferative effects, highlighting the need for further research. CCNG2 antibodies thus serve as essential reagents for elucidating the protein's dual regulatory mechanisms and therapeutic potential.